Original contribution
Metered dose inhaler salbutamol treatment of asthma in the ED: Comparison of two doses with plasma levels

https://doi.org/10.1016/S0735-6757(96)90121-7Get rights and content

Abstract

Two cumulative doses of salbutamol delivered by metered dose inhaler (MDI) with a pear-shaped spacer were compared (400 μg vs 600 μg at 10-minute intervals). Twenty-two patients (mean age 35.1 ± 11.1 years) with acute exacerbation of asthma were randomly assigned, in a doubleblind fashion, to receive salbutamol delivered with MDI into a spacer device in 4 puffs at 10-minute intervals (100 μg or 150 μg per actuation) during 3 hours (1200 μg or 1800 μg each 30 minutes). Mean peak expiratory flow rate (PEFR) and forced expiratory volume in the first second (FEV1) improved significantly over baseline values for both groups (P < .001). Nevertheless, there were no significant differences between both groups for PEFR and FEV1 at any time point studied. A significant net reduction of heart rate was observed in the 400 μg group (P < .01). On the other hand, a significant increase in heart rate was observed in the 600 μg group (P < .001). The QTc interval did not show a significant prolongation, and the two groups presented moderate decreases of serum potassium levels. There was a significant dose-related increase (P = .027) in Sao2. Additionally, the 600 μg group generated a serum glucose level increase from 0.85 ± 0.12 mg/100 mL to 1.04 ± 0.25 mg/100 mL (P = .02). At the end of treatment, the salbutamol plasma levels were 10.0 ± 1.67 ng/mL for the 400 μg group, and 14.0 ± 2.17 for the 600 μg group (P = .001). Finally, the overall symptom score in patients in the 600 μg group was significantly greater than the score in the low dose group (P = .02), with a higher incidence in 4 symptoms (tremor, headache, palpitations, and anxiety). These data support the notion that the treatment of acute asthma patients in the emergency department setting with salbutamol, 2.4 mg/h, delivered by MDI and spacer (4 puffs at 10-minute intervals) produces satisfactory bronchodilation, low serum concentration, and minimal extrapulmonary effects. However, an increase of 50% of the dose (600 μg at 10-minute intervals) produced a nonsignificant, slightly better therapeutic response but with greater side effects, probably related to higher salbutamol levels.

References (34)

  • RY Lin et al.

    High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol

    Chest

    (1993)
  • ER McFadden

    Clinical physiological correlates in asthma

    J Allergy Clin Immunol

    (1986)
  • CS Wong et al.

    Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma

    Lancet

    (1990)
  • A Tal et al.

    Arterial oxygen desaturation following salbutamol inhalation in acute asthma

    Chest

    (1984)
  • National Heart, Lung and Blood Institute, National Asthma Education Program Expert Panel Report

    Guidelines for the diagnosis and management of asthma

    (1991)
  • RM Nowak

    Inhaled beta agonists and acute asthma

    Am J Emerg Med

    (1995)
  • MJ Ward

    Clinical trials in acute severe asthma: Are type II errors important?

    Thorax

    (1986)
  • Cited by (36)

    • Targeting mucus barrier in respiratory diseases by chemically modified advanced delivery systems

      2022, Chemico-Biological Interactions
      Citation Excerpt :

      The delivery of salbutamol via pressurized metered-dose inhaler and dry powder inhaler ensures a targeted delivery and high local drug concentration with a minimal systemic exposure [53]. However, salbutamol shows a prompt absorption to the systemic circulation in 10–15 min of administration via metered-dose inhaler [54]. High membrane permeability and water solubility of salbutamol lowers the drug duration and decreases the local concentration of the drug at the deliberated site.

    • Drug-induced tremors

      2005, Lancet Neurology
      Citation Excerpt :

      In large clinical trials, 7–20% of patients complained of tremor due to inhaled salbutamol with similar numbers of patients complaining of tremor due to isoprenaline (14%).79,80 Tremor associated with β2-adrenergic agonists is dose-related81,82 and may occur more commonly with oral dosing. Salmeterol, a β2-adrenergic agonist with a long half-life, is associated with tremor in 1·7% of patients chronically treated with 50 μg twice daily, although 5·7% of patients receiving a single dose of 100 μg salmeterol reported tremor.83

    • Acute asthma in adults: A review

      2004, Chest
      Citation Excerpt :

      However, the resulting fall in Pao2 is small, of short duration, and generally of negligible significance. Available data about the use of high doses of β2-agonists support the concept that treatment of patients with AA with albuterol, 2.4 mg/h (four puffs at 10-min intervals by pMDI and spacer) or 2.5 mg every 20 min by nebulization, produces satisfactory bronchodilation, low serum concentration, and minimal side effects.7778138139150 In some patients with particularly severe conditions, it may be necessary to increase the dose to one or more puffs every 10 to 20 s.

    View all citing articles on Scopus
    View full text